Key Takeaways
- TARGAN has entered into a $100 million financing agreement with Symbiotic Capital to accelerate the deployment of its poultry technologies.
- The deal, closed in late 2025, included an initial funded tranche of $30 million to strengthen the company’s balance sheet.
- Proceeds will support the commercial scaling of WingScan™, a high-speed avian sex identification system.
- TARGAN reported doubling its revenue from 2024 to 2025, with further significant growth projected for the 2026 fiscal year.
Strategic Capital Infusion for TARGAN
TARGAN, a prominent animal health and AgTech firm, has finalized a $100 million credit facility with Symbiotic Capital, a private credit fund focused on the healthcare and life sciences sectors. This financing replaces the company's previous senior lender and provides the liquidity necessary to support an aggressive commercial roadmap. The capital is designated for scaling global operations and preparing a new wave of technologies for market entry throughout 2026 and 2027.
Scaling WingScan™ Technology Globally
The primary driver for this investment is the global momentum of WingScan™, TARGAN’s flagship automated system. The technology utilizes artificial intelligence and high-speed imaging to identify the gender of chicks, a process historically performed manually. By automating this stage of production, the system allows hatcheries to handle up to 160,000 chicks per hour with over 98% accuracy. This efficiency enables gender-specific rearing strategies that improve uniformity and performance across the poultry value chain.
Commercial Growth and Market Expansion
TARGAN has experienced a period of rapid financial expansion, with year-over-year revenue doubling into 2025. The company is currently expanding its footprint across the United States, Europe, and South America. The new funding will allow TARGAN to invest in regional service infrastructure and increased manufacturing capacity to meet the rising demand for precision automation in animal protein production.
